Accordingly, the National Comprehensive Cancer Network (NCCN) NSCLC guidelines had recommended the routine detection of EGFR or ERBB2 mutations, or ALK, ROS1, or RET fusions prior to treatment. Here, EGFR is linked to non-small cell lung carcinoma.